In this episode, I discuss Samsara Vision's SING IMT and its benefits of vision improvement for patients with AMD with Rebecca Kammer, OD, PhD. Brought to you by Alcon · Welcome to another exciting episode of Eye Care insider :14 · Intro for Rebecca Kammer, OD, PhD :27 · Dr. Kammer's background 1:28 · Defining late-stage AMD patients and treatments available 5:11 · The SING IMT 9:46 · <a href= "https://www.oraconnects.com/find-a-trial-amd-old/">US Concerto Study Website</a> – to learn more about the study 13:13 · Visual acuity and the SING IMT 13:48 · US trial, recruitment and patient eligibility 17:18 · Contact toll-free 1-866-393-3767 discuss eligibility, participation and questions 20:39 · SING IMT as an option for patients 22:55 · Thanks for listening 27:30 We'd love to hear from you! Send your comments/questions to Dr. Mali at <a href= "mailto:eyecareinsider@healio.com">eyecareinsider@healio.com</a>. Follow us on Twitter <a href= "https://twitter.com/HRheuminations">@Healio_OSN</a>. You can reach Dr. Kammer at <a href= "mailto:rkammer@samsaravision.com">rkammer@samsaravision.com</a>. Rebecca Kammer, OD, PhD, is the vice president of worldwide clinical and medical affairs for Samsara Vision, Inc., an adjunct professor at University of California, Irvine and a diplomate in low vision of the American Academy of Optometry. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI. Kammer reports being a clinical advisor to Biovisics and Eyedaptic.

<description>&lt;p class="MsoNormal"&gt;In this episode, I discuss Samsara Vision's SING IMT and its benefits of vision improvement for patients with AMD with &lt;strong&gt;Rebecca Kammer, OD, PhD&lt;/strong&gt;.&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;em&gt;Brought to you by Alcon&lt;/em&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpFirst" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Welcome to another exciting episode of Eye Care insider &lt;strong&gt;&lt;em&gt;:14&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Intro for Rebecca Kammer, OD, PhD &lt;strong&gt;&lt;em&gt;:27&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Dr. Kammer's background &lt;strong&gt;&lt;em&gt;1:28&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Defining late-stage AMD patients and treatments available &lt;strong&gt;&lt;em&gt;5:11&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;The SING IMT &lt;strong&gt;&lt;em&gt;9:46&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;&lt;a href= "https://www.oraconnects.com/find-a-trial-amd-old/"&gt;US Concerto Study Website&lt;/a&gt; – to learn more about the study &lt;strong&gt;&lt;em&gt;13:13&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Visual acuity and the SING IMT &lt;strong&gt;&lt;em&gt;13:48&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;US trial, recruitment and patient eligibility &lt;strong&gt;&lt;em&gt;17:18&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Contact toll-free &lt;strong&gt;1-866-393-3767&lt;/strong&gt; discuss eligibility, participation and questions &lt;strong&gt;&lt;em&gt;20:39&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;SING IMT as an option for patients &lt;strong&gt;&lt;em&gt;22:55&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpLast" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Thanks for listening &lt;strong&gt;&lt;em&gt;27:30&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoNormal"&gt;We'd love to hear from you! Send your comments/questions to Dr. Mali at &lt;a href= "mailto:eyecareinsider@healio.com"&gt;eyecareinsider@healio.com&lt;/a&gt;. Follow us on Twitter &lt;a href= "https://twitter.com/HRheuminations"&gt;@Healio_OSN&lt;/a&gt;. You can reach Dr. Kammer at &lt;a href= "mailto:rkammer@samsaravision.com"&gt;rkammer@samsaravision.com&lt;/a&gt;.&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;strong&gt;Rebecca Kammer, OD, PhD,&lt;/strong&gt; is the vice president of worldwide clinical and medical affairs for Samsara Vision, Inc., an adjunct professor at University of California, Irvine and a diplomate in low vision of the American Academy of Optometry.&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;strong&gt;Disclosures:&lt;/strong&gt; Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI. Kammer reports being a clinical advisor to Biovisics and Eyedaptic.&lt;/p&gt;</description>

Eye Care Insider

Samsara Vision's SING IMT: Game Changer for the Advanced AMD Patient

Samsara Vision's SING IMT: Game Changer for the Advanced AMD Patient

Description